{"id":8047,"date":"2024-11-01T16:00:00","date_gmt":"2024-11-01T07:00:00","guid":{"rendered":"https:\/\/www.zacros.co.jp\/?post_type=topics&#038;p=8047"},"modified":"2024-11-01T11:28:58","modified_gmt":"2024-11-01T02:28:58","slug":"announcement-of-capital-and-business-alliance-with-revorf-co-ltd","status":"publish","type":"topics","link":"https:\/\/www.zacros.co.jp\/en\/topics\/topic-8047\/","title":{"rendered":"Announcement of Capital and Business Alliance with Revorf Co., Ltd"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1000\" height=\"400\" src=\"https:\/\/www.zacros.co.jp\/wp-content\/uploads\/2024\/10\/Revorf\u30c8\u30d4\u30c3\u30af\u30b91000-x-400-px.png\" alt=\"\" class=\"wp-image-8045\" srcset=\"https:\/\/www.zacros.co.jp\/wp-content\/uploads\/2024\/10\/Revorf\u30c8\u30d4\u30c3\u30af\u30b91000-x-400-px.png 1000w, https:\/\/www.zacros.co.jp\/wp-content\/uploads\/2024\/10\/Revorf\u30c8\u30d4\u30c3\u30af\u30b91000-x-400-px-300x120.png 300w, https:\/\/www.zacros.co.jp\/wp-content\/uploads\/2024\/10\/Revorf\u30c8\u30d4\u30c3\u30af\u30b91000-x-400-px-768x307.png 768w, https:\/\/www.zacros.co.jp\/wp-content\/uploads\/2024\/10\/Revorf\u30c8\u30d4\u30c3\u30af\u30b91000-x-400-px-560x224.png 560w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><\/figure>\n\n\n\n<p>ZACROS Corporation, announce the investment of 49.98 million yen in the biotech startup Revorf Co., Ltd. (hereinafter referred to as \u201cRevorf\u201d) through a third-party allocation of shares on October 30, in order to accelerate the expansion of its medium- to long-term growing project of cell culture contract manufacturing business. Through this capital and business alliance, ZACROS will develop an efficient manufacturing process for neoself antigen-expressing cells, utilized by Revorf for its testing method, and undertake their commercial production.<\/p>\n\n\n\n<p>\u25a0Overview of the Investee Company<br>\uff08\uff11\uff09Company Name: Revorf Co., Ltd.<br>\uff08\uff12\uff09Location: 2-1-17 Nihonbashi, Chuo-ku, Tokyo<br>\uff08\uff13\uff09Established: November 2019<br>\uff08\uff14\uff09Representative: Shinichi Sueda (CEO)<br>\uff08\uff15\uff09Business Description: Development of diagnostic and therapeutic agents for autoimmune diseases<br>\u3000\u3000\u3000\u3000\u3000\u3000\u3000\u3000\u3000\u3000\u3000\u3000\u3000\u3000Development of diagnostic and therapeutic agents for infectious diseases<br>\uff08\uff16\uff09URL\uff1a<a rel=\"noreferrer noopener\" href=\"https:\/\/www.revorf.jp\/\" target=\"_blank\">https:\/\/www.revorf.jp\/<\/a><\/p>\n\n\n\n<p>This strategic partnership will create synergies leveraging the strengths of both companies, therefore contributing to the advancement of medical technology.<\/p>\n\n\n\n<p>Please refer to the <a href=\"https:\/\/ssl4.eir-parts.net\/doc\/7917\/ir_material12\/239571\/00.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">news release<\/a> for more details.<\/p>\n","protected":false},"featured_media":8055,"template":"","topics_category":[11],"class_list":{"0":"post-8047","1":"topics","2":"type-topics","3":"status-publish","4":"has-post-thumbnail","6":"topics_category-wellness","7":"en-US","8":"c-entry"},"acf":[],"_links":{"self":[{"href":"https:\/\/www.zacros.co.jp\/wp-json\/wp\/v2\/topics\/8047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.zacros.co.jp\/wp-json\/wp\/v2\/topics"}],"about":[{"href":"https:\/\/www.zacros.co.jp\/wp-json\/wp\/v2\/types\/topics"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.zacros.co.jp\/wp-json\/wp\/v2\/media\/8055"}],"wp:attachment":[{"href":"https:\/\/www.zacros.co.jp\/wp-json\/wp\/v2\/media?parent=8047"}],"wp:term":[{"taxonomy":"topics_category","embeddable":true,"href":"https:\/\/www.zacros.co.jp\/wp-json\/wp\/v2\/topics_category?post=8047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}